Capsugel buys capsule filling technology Xcelodose
Capsugel has expanded its equipment product offering to its pharmaceutical customers by buying the powder micro-dosing technology Xcelodose from Meridica.
Capsugel has expanded its equipment product offering to its pharmaceutical customers by buying the powder micro-dosing technology Xcelodose from Meridica.
Xcelodose offers automated capsule filling for preparation of early stage clinical trial supplies.
Developed by the UK-based drug delivery company Meridica (now part of Pfizer), the micro-dosing technology can handle drug compounds without bulking agent or excipient and can fill up to several hundred capsules/hr with programmable weights, from 100µg to several hundreds of milligrams with a relative standard deviation of less than 2%.
David Edwards will continue as director re-sponsible for the Xcelodose business and will be located at Capsugel's UK offices in Cambridge.
T +44 1223 598480
www.xcelodose.com